Public Company

Cognition Therapeutics, Inc.


Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics targeting age-related degenerative diseases and disorders specific to the central nervous system, or CNS, and retina with a goal to develop treatments that can modify the diseases in patients with these disorders. The company has expert experience in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses. It also acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina.


Founded 2007
Type Public
Location Pennsylvania, USA Purchase, Harrison, New York, USA


CGTX $2.00 0.50% $0.01

Latest News

Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease Dec 22, 2022 GlobeNewswire Inc. - Features Alzheimer’s Experts: Christopher van Dyck, M.D. and Anton Porsteinsson, M.D. -
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023" Dec 21, 2022 GlobeNewswire Inc. PURCHASE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s management team will...
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812 Dec 15, 2022 GlobeNewswire Inc. SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech Republic SHINE Study Expanded from USA to Include sites in Spain,...
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session Dec 01, 2022 Benzinga Gainers Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24. Vapotherm, Inc. (NASDAQ: VAPO) gained 48.8% to $1.3250. The Alkaline Water Company Inc. (NASDAQ:...
Why Okta Shares Are Trading Higher By Around 14%; Here Are 27 Stocks Moving Premarket Dec 01, 2022 Benzinga Gainers Pacifico Acquisition Corp. (NASDAQ: PAFO) shares rose 40.9% to $7.58 in pre-market trading after dipping around 43% on Wednesday. Otonomy, Inc. (NASDAQ: OTIC) rose...